ClinicalTrials.gg
CompletedNCT03490786Updated Apr 6, 2018

A Dose Escalating Study to Assess the Safety and Tolerability of GT-001

A Phase 1 interventional study of GT-001 in Feeding and Eating Disorders, sponsored by Gila Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-04-06.

Sponsored by Gila Therapeutics, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2017, 9 years 3 months ago, and no results have been posted to the registry.
  • Registered 7 months after the study started (first participant enrolled Jul 2017, registered Feb 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 259 studies in Feeding and Eating Disorders with a site in United States — 36 open to participants now, 50 under way, none of them phase 3. Feeding and Eating Disorders · United States.

Enrollment
190th of 215
12 · median 66
Started
2017
with 15 others
Phase 1
17 of 259
1 open now
Registered
133rd of 259
by date

Among the 259 studies in Feeding and Eating Disorders with a site in United States, this one is the 190th largest by enrollment of the 215 interventional ones that give a count, is one of 16 that started in 2017, is one of 17 in phase 1, and was the 133rd registered.

Feeding and Eating Disorders

645 studies on the registry are indexed under Feeding and Eating Disorders; 153 are open to participants now.

Browse Feeding and Eating Disorders studies →

Open to participants now

36 of the 259 studies in Feeding and Eating Disorders with a site in United States are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 100 Feeding and Eating Disorders studies recruiting now, 31 (31%) set no upper age limit and 67 (67%) stop at 75 or younger; 45 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 259 studies in Feeding and Eating Disorders with a site in United States, or all of them as a file.
02

Study summary

Dose escalation study of GT-001

Read the detailed description

This is a dose-escalation design trial. Twelve evaluable subjects (n=12) with BMIs of 30 to 40 kg/m2 will receive a single dose of placebo followed by study drug applied directly to the surface of the tongue mucosa with a disposable pipette followed by a one-day washout. A total of seven (7) doses will escalate to a dose of 2.5 mg.

03

Conditions studied

  • Feeding and Eating Disorders

Keywords

  • GT-001
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult participants with obesity class I and II ( 30-40 kg/m2)
  • Willing and able to provide written after reviewing the design and risks of the study and prior to completing any study-related procedure
  • Willing and able to understand and comply with all study procedures and requirements.
  • Women must have a predictable menstrual cycle and taking either monophasic oral , or transdermal (Ortho Evra and Evra) at least one month prior to the study.
  • Alternatively, women (defined as period of spontaneous amenorrhea for more than 1 year), and bilateral oophorectomized women are allowed into the study.
  • Must be able to complete the Weight Efficacy Life-Style Questionnaire (WEL).
  • Systolic blood pressure 100-160 mmHg at the time of screening.
  • Stable and compliant treatment with oral medications for at least 4 weeks prior to screening.
  • Women of child bearing potential () and males must agree to use at least two forms of contraception, of which one includes a barrier method (male condom) by the male partner, during study participation and continued for at least 90 days after the conclusion of the final dose.
  • In addition, sperm donations by male subjects are not permitted during the subject's participation in the research study and for at least 90 days after the conclusion of the final dose. This criterion may be waived for male subjects who have undergone a vasectomy at least 6 months prior to screening.
  • Willing and able to abstain from drugs, , and tobacco during study participation.
  • Must have abstained from alcohol use for 48 hours prior to study day 1 through the duration of the study
  • Must have abstained from any tobacco- or nicotine-containing products (e.g., cigarettes, e-cigarettes, pipes, cigars, chewing tobacco, nicotine patches, nicotine lozenges, or nicotine gum) within 6 months prior to study day 1.
  • History of stable weight for at least 3 months prior to study entry.

Exclusion criteria

Exclusion Criteria:

  • Known or allergy to Peptide YY, Pancreatic polypeptide (PP), other similar polypeptides or related compounds
  • Known mutation to PYY or Y2 receptor gene (i.e., Pima Indians)
  • Any medical condition for which modification of the medication that cannot be performed either safely or feasibly. Chronic diseases including metabolic, psychiatric, cardiovascular, endocrine, etc. for which the participant is not stable for 60 days prior to study initiation
  • Female subjects who are pregnant or breast-feeding
  • Female subjects of child bearing potential who are not on oral or using biphasic or triphasic oral contraceptives
  • women who have not had a period of spontaneous amenorrhea for more than 1 year Unstable psychological or behavior profile (e.g., anxiety, depression)
  • Subjects with fasting glucose levels greater than 125 mg/dl.
  • Type I or Type II diabetes
  • Poor dentition or oral pathology
  • Unable or unwilling to give written .
  • Temperature > 38°C (oral or equivalent)
  • Sepsis or active infection requiring IV antimicrobial treatment
  • Acute myocarditis or hypertrophic obstructive, restrictive, or constrictive cardiomyopathy (not including restrictive mitral filling patterns)
  • Major neurologic event, including cerebrovascular events within 60 days prior to study initiation
  • Significant pulmonary disease (e.g., history of oral daily dependency, history of CO2 retention or need for intubation for acute exacerbation, or currently receiving IV steroids)
  • Known hepatic impairment as indicated by any of the following:

    • Total > 3 mg/dl
    • Albumin \< 2.8 mg/dl, with other signs or symptoms of hepatic dysfunction
    • Increased ammonia levels, if performed, with other signs or symptoms of hepatic dysfunction
  • Any organ transplant recipient or currently listed (anticipated in the next 60 days) for transplant
  • Major surgery within 30 days prior to study initiation
  • Positive screen for (HbsAg, Hepatitis B Surface Antigen), (anti-HCV, Hepatitis C Antibody), or (anti-HIV 1/2)
  • Received an intervention within 30 days prior to study initiation, or have received PYY3-36, GLP-1 agonists, insulin or DPP-IV inhibitors in a previous clinical trial.
  • Consumption of alcohol within 48 hours prior to study day1 and through study day 15 or early termination
  • Use of any tobacco- or nicotine-containing products (e.g., cigarettes, e-cigarettes, pipes, cigars, chewing tobacco, nicotine patches, nicotine lozenges, or nicotine gum) within 6 months
  • A positive urine drug screen for ethanol, cotinine, cocaine, THC, barbiturates, amphetamines, benzodiazepines, and/or opiates
  • A history of difficulty with donating blood, or having donated blood or blood products within 45 days prior to study initiation
  • Use of weight loss drugs Orlistat (Alli or Xenical), Qsymia, Phentermine, Contrave, Lorcaserin, liraglutide, topiramate or exenatide within the last six months.
  • Concurrent use of antihistamines
  • Any condition that, in the opinion of the Investigator or Medical Monitor, would render the subject unsuitable for participation in the study
  • Unable to consume the test meal
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Dose escalation

    Single arm dose escalation.

    Drug: GT-001

Interventions

  • DrugGT-001

    PK, PD Study to Determine Safety of Escalating Doses of GT-001

    Also known as: PYY(3-36), Peptide YY (3-36)

06

What researchers measure

Primary outcomes

  1. Demonstrate safe doses of PGT-001 for reduction of body weight in obese volunteers.

    Measures of the safety and tolerability of GT-001 include documentation of adverse events and changes (compared to baseline) in vital signs, physical examination, and laboratory tests.

    Time frame: approximately two weeks

Secondary outcomes

  1. Dose-relationship of adverse events

    Incidence, severity and dose-relationship of adverse events as well as changes in physical examinations, vital signs and/or laboratory evaluations as a measure of safety and tolerability.

    Time frame: approximately two weeks

  2. Dose relationship to peak plasma concentration of GT-001

    Peak plasma concentration of GT-001 to assess relationship to dose of GT-001.

    Time frame: Approximately two weeks

  3. Dose relationship to hunger and satiety

    Measurement of hunger and satiety will be conducted using visual analog scores to assess a relationship to dose of GT-001

    Time frame: approximately two weeks

07

Study locations

1 site
  • Orange County Research Center
    Tustin, California 92780, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2017 to primary completion in Aug 2017, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2018
First posted
Apr 6, 2018
StartActual
Jul 16, 2017
Primary completionActual
Aug 9, 2017
CompletionActual
Oct 2, 2017
Last update
Apr 6, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03490786
Lead sponsor
Gila Therapeutics, Inc.
Responsible party
Sponsor
First posted
Apr 6, 2018
Start date
Jul 16, 2017
Primary completion
Aug 9, 2017
Completion
Oct 2, 2017
Last update
Apr 6, 2018

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Peptide YY human (3-36)

Start the discussion